Diabetes Drug May Benefit All Heart Failure Patients

September 7, 2022 by Dan McCue
Diabetes Drug May Benefit All Heart Failure Patients
(Photo by Robina Weermeijer via UnSplash)

BOSTON — Researchers from Brigham and Women’s Hospital have uncovered new evidence that shows drugs originally developed to treat type 2 diabetes may benefit a wide range of patients with heart failure. 

The research was presented at the recent European Society of Cardiology conference and published simultaneously in The New England Journal of Medicine and The Lancet.

It stems from the largest trial to date of heart failure patients with mildly reduced or preserved ejection fraction.

During that trial, the Brigham and Women’s Hospital researchers, in collaboration with a team from the University of Glasgow, in Scotland, showed that dapagliflozin, which had previously been shown to benefit patients with heart failure with reduced ejection fraction, is likely to also reduce cardiovascular death and hospitalization for patients with mildly reduced or preserved ejection fraction — a population of millions of patients who have had limited therapeutic options in the past. 

A meta-analysis that included two clinical trials further strengthened the evidence that this class of drugs may provide protection for a wide range of heart failure patients.

“In the largest and most inclusive trial of heart failure with mildly reduced or preserved ejection fraction, we found that treatment with the SGLT2 inhibitor dapagliflozin can benefit patients across the full spectrum of heart failure,” said Dr. Scott Solomon, of the Brigham’s Division of Cardiovascular Medicine. 

“These findings establish SGLT2 inhibitors as foundational treatment for patients living with heart failure, regardless of ejection fraction, to help prevent hospitalization and morbidity and to extend meaningful survival and improve health-related quality of life. These are the outcomes that matter most to patients and to clinicians — to keep patients feeling well and living longer,” he said.

Dapagliflozin is a sodium-glucose co-transporter-2 inhibitor — a class of drugs that cause the body to excrete sugar in urine. 

In addition to controlling blood sugar in patients with diabetes, SGLT-2 inhibitors have been shown to provide significant cardiovascular and kidney disease benefits. 

The trial, which was conducted at 353 sites across 20 countries, was designed to determine whether dapagliflozin would decrease cardiovascular morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction. 

The trial enrolled patients who were 40 or older and had symptomatic heart failure with an ejection fraction of greater than 40%, including mildly reduced ejection fraction and preserved ejection fraction, as well as patients who had previously had reduced ejection fraction that had improved to greater than 40%, and in both the outpatient and inpatient setting. 

More than 6,000 participants were randomized to receive dapagliflozin or placebo and followed for a median of 2.3 years. The primary endpoint was a composite of cardiovascular death or worsening heart failure.

Dapagliflozin significantly reduced the primary composite endpoint by 18%. Worsening heart failure occurred in 368 participants (11.8%) in the dapagliflozin group compared to 455 participants (14.5%) in the placebo group. 

Cardiovascular death in these groups occurred in 231 (7.4%) and 261 (8.3%) participants, respectively. Key secondary outcomes were also significantly reduced, including total heart failure hospitalizations and total symptom burden.

The authors note that the work has some limitations. Less than 5% of patients enrolled in DELIVER were Black, and the COVID pandemic limited symptom assessment after March 2020.

“There are more than 64 million people worldwide affected by heart failure, half of whom have mildly reduced or preserved ejection fraction,” said Solomon.

“Our goal is to rigorously and scientifically evaluate potential treatments so that we can provide the best evidence-based care to help them lead longer, healthier lives.”

Dan can be reached at [email protected] and at https://twitter.com/DanMcCue.

A+
a-
  • diabetes
  • heart attacks
  • heart failure
  • off-label uses
  • prescription drugs
  • In The News

    Health

    Voting

    Health

    May 16, 2025
    by Dan McCue
    YouTube Personality ‘Doctor Mike’ Finally Gets Taken Seriously

    WASHINGTON — It’s a moment “Doctor Mike” Varshavski still describes as both a blessing and a curse. Here he was,... Read More

    WASHINGTON — It’s a moment “Doctor Mike” Varshavski still describes as both a blessing and a curse. Here he was, a young doctor in the middle of his residency in 2015, when thanks to his presence on Instagram, he found himself in the pages of People... Read More

    Mandating ‘Preventive Services’ Not What the Doctor Ordered

    The Affordable Care Act, aka Obamacare, has been anything but affordable. Despite all the talk about “bending the cost curve,”... Read More

    The Affordable Care Act, aka Obamacare, has been anything but affordable. Despite all the talk about “bending the cost curve,” benefit costs have far outpaced inflation since the 2010s and national annual health care spending is now an astounding $5 trillion. The good news is that the Supreme Court... Read More

    Missouri Lawmakers Approve Referendum to Repeal Abortion-Rights Amendment

    JEFFERSON CITY, Mo. (AP) — Six months after Missouri voters approved an abortion-rights amendment, Republican state lawmakers on Wednesday approved... Read More

    JEFFERSON CITY, Mo. (AP) — Six months after Missouri voters approved an abortion-rights amendment, Republican state lawmakers on Wednesday approved a new referendum that would seek the amendment's repeal and instead ban most abortions with exceptions for rape an incest. The newly proposed constitutional amendment would... Read More

    May 14, 2025
    by Tom Ramstack
    EPA Revises Rules on ‘Forever Chemicals’ Found in Drinking Water

    WASHINGTON — The Environmental Protection Agency announced Wednesday that it is rolling back limits on the "forever chemicals" that have... Read More

    WASHINGTON — The Environmental Protection Agency announced Wednesday that it is rolling back limits on the "forever chemicals" that have been found in the nation's drinking water. The chemicals, known as PFAS, have been linked to cancer and reproductive health problems. They are commonly used in... Read More

    May 14, 2025
    by Dan McCue
    Kennedy Defends ‘Streamlining’ of HHS During Budget Hearings 

    WASHINGTON — Testifying on Capitol Hill for the first time as the nation’s leading health official, Health Secretary Robert Kennedy... Read More

    WASHINGTON — Testifying on Capitol Hill for the first time as the nation’s leading health official, Health Secretary Robert Kennedy Jr. on Wednesday defended his bare bones request for $94 billion to run his department, as well as steps he’s taken since January to dramatically cut... Read More

    Maryland Gov. Moore Signs Bill to Tap Unused ACA Insurance Funds for Abortion Grant Program

    ANNAPOLIS, Md. (AP) — Maryland will become the first state to use money collected from a surcharge on insurance plans... Read More

    ANNAPOLIS, Md. (AP) — Maryland will become the first state to use money collected from a surcharge on insurance plans sold under the Affordable Care Act to fund a program to pay for abortions, regardless of a patient's insurance coverage, under a measure signed into law Tuesday by... Read More

    News From The Well
    scroll top